Powolania Jona Congletona do zarządu IMUX

Congleton's board appointment will improve institutional investor confidence in IMUX governance, reflected in increased trading volume averaging at least 25% above the 60-day pre-announcement average within the 60 days following the announcement.

The board appointment of Jon Congleton, with his biopharmaceutical executive background, signals IMUX's strategic pivot toward clinical advancement, leading to at least one positive clinical trial announcement or partnership agreement within 120 days.

Jon Congleton's appointment to Immunic Inc (IMUX) board will catalyze positive market sentiment, resulting in stock price appreciation of at least 8-12% within 60 days of announcement.